Fundie bullish on CSL shares after praising the 'special business'

Earnings growth justifies current valuations, these experts say.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have been a mixed bag in 2024. Whilst the broader market has marched higher, CSL has pushed sideways for the bulk of the year.

Several fund managers now see CSL as an attractive option for their portfolios, given this relative underperformance.

CSL shares are currently trading at $288.81, down nearly 5% in the past month of trade. Let's see why these fundies are bullish on the biotech giant.

CSL shares still offer value

Valuation is a core function in finance, and what you pay to buy an asset matters a lot. But a comparison next to growth factors is needed to gauge price versus value.

As Warren Buffett said – price is what you pay, value is what you get.

Investors Mutual (IML) is bullish on CSL and expects significant earnings growth from the biotech giant in the coming years.

IML's Daniel Moore notes that CSL's earnings growth is comparable to that of many tech companies, except with more palatable valuations.

So despite trading at a high price-to-earnings (P/E) ratio of over 35 at the time of writing, Moore believes that CSL's steady earnings growth justifies its premium valuation, labelling it a "special business" in doing so. Speaking to The Australian Financial Review, he said:

Even when you look at some of the tech companies, their earnings growth is not much higher than CSL, but they trade on multiples considerably higher.

There's not too many businesses that can compound at that earnings growth rate. And we think it's quite a special business.

Meanwhile, those at Bennelong Australian Equity Partners also like CSL on a valuation front.

Whilst the broad market has tracked higher, CSL shares have remained fairly stagnant in terms of capital growth.

Bennelong portfolio manager Brad Clibborn believes this mismatch means the market could be undervaluing CSL. Especially when looking at earnings growth forecasts. Also speaking to The Australian Financial Review:

Where we sit today, though, we believe expectations have rebased and the company is now on track to deliver double-digit earnings growth over the medium and long term. Demand for the company's core immunoglobulin product continues to grow strongly, CSL has new products coming, and yield improvement initiatives in the IG business should drive margin recovery and add to earnings growth.

Brokers also bullish

Bennelong and Investors Mutual aren't the only firms that are bullish on CSL shares. Several top brokers rate the stock a buy as well.

Bell Potter rates CSL a buy with a price target of $316.50. It cited CSL's dominance in the plasma industry and its product pipeline and expects plenty of earnings growth in the near future.

Macquarie also issued a buy rating on CSL shares, setting a higher price target of $330 apiece.

The broker is a little more optimistic about CSL's future, particularly with its garadacimab therapy, which is expected to begin generating revenue soon.

According to CommSec, consensus also rates CSL shares a buy. As such, multiple analysts expect further upside.

Foolish takeaway

CSL shares have lagged the broader market this year. However, according to several experts, the biotech giant is now undervalued and could be well-positioned for growth.

In the last 12 months, the stock has climbed more than 14%.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »